MAP2K7 and glioblastoma: While evidence has been limited, one case study of two patients diagnosed with GBM harboring BRAFV600E mutations demonstrated tumor regression and control after treatment with a dual BRAF-MEK inhibitor, though treatment resistance developed, limiting survival to 7 and 7.5 months respectively17.